Iron facilitator LS081 reduces hypoxia-inducible factor-1α protein and functions as anticancer agent in hepatocellular carcinoma

Cancer Science

Volumn 103, Issue 4, 2012, Pages 767-774

  Tanaka, Hiroki ^a   Li, Zhen ^b   Ikuta, Katsuya ^a   Addo, Lynda ^a   Akutsu, Hiroaki ^a   Nakamura, Masao ^a   Sasaki, Katsunori ^a   Ohtake, Takaaki ^a   Fujiya, Mikihiro ^a   Torimoto, Yoshihiro ^a   Glass, Jonathan ^b   Kohgo, Yutaka ^a  

^a ASAHIKAWA MEDICAL COLLEGE   (Japan)

^b LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMMONIUM CITRATE; ANTINEOPLASTIC AGENT; HYPOXIA INDUCIBLE FACTOR 1ALPHA; LS 081; PROTEASOME; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL STRAIN HEK293; CELL STRAIN HEP3B; CELL STRAIN HEPG2; EMBRYO; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IRON TRANSPORT; LIVER CELL CARCINOMA; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION;

ANIMALS; CARCINOMA, HEPATOCELLULAR; CELL LINE; CELL PROLIFERATION; HEK293 CELLS; HEP G2 CELLS; HUMANS; HYDRAZONES; HYDROXYLATION; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IRON; MICE; NIACINAMIDE; RNA, MESSENGER;

EID: 84862800293     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2011.02192.x     Document Type: Article

References (29)

1. Wang GL, Semenza GL. Purification and characterization of hypoxia-inducible factor 1. J Biol Chem 1995; 270: 1230-7.
2. 2 tension. Proc Natl Acad Sci USA 1995; 92: 5510-4.
3. Tanimoto K, Makino Y, Pereira T, Poellinger L. Mechanism of regulation of the hypoxia-inducible factor-1alpha by the von Hippel-Lindau tumor suppressor protein. EMBO J 2000; 19: 4298-309.
4. Ohh M, Park CW, Ivan M et al. Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein. Nat Cell Biol 2000; 2: 423-7.
5. Maxwell PH, Wiesener MS, Chang GW et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 1999; 399: 271-5.
6. Kamura T, Sato S, Iwai K et al. Activation of HIF1alpha ubiquitination by a reconstituted von Hippel-Lindau (VHL) tumor suppressor complex. Proc Natl Acad Sci USA 2000; 97: 10430-5.
7. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003; 3: 721-32.
8. Gray MJ, Zhang J, Ellis LM et al. HIF-1alpha, STAT3, CBP/p300 and Ref-1/APE are components of a transcriptional complex that regulates Src-dependent hypoxia-induced expression of VEGF in pancreatic and prostate carcinomas. Oncogene 2005; 24: 3110-20.
9. Jiang BH, Agani F, Passaniti A, Semenza GL. V-SRC induces expression of hypoxia-inducible factor 1 (HIF-1) and transcription of genes encoding vascular endothelial growth factor and enolase 1: involvement of HIF-1 in tumor progression. Cancer Res 1997; 57: 5328-35.
10. Chan DA, Sutphin PD, Denko NC, Giaccia AJ. Role of prolyl hydroxylation in oncogenically stabilized hypoxia-inducible factor-1alpha. J Biol Chem 2002; 277: 40112-7.
11. Tanaka H, Yamamoto M, Hashimoto N et al. Hypoxia-independent overexpression of hypoxia-inducible factor 1alpha as an early change in mouse hepatocarcinogenesis. Cancer Res 2006; 66: 11263-70.
12. Bianchi L, Tacchini L, Cairo G. HIF-1-mediated activation of transferrin receptor gene transcription by iron chelation. Nucleic Acids Res 1999; 27: 4223-7.
13. Knowles HJ, Raval RR, Harris AL, Ratcliffe PJ. Effect of ascorbate on the activity of hypoxia-inducible factor in cancer cells. Cancer Res 2003; 63: 1764-8.
14. Semenza GL. Evaluation of HIF-1 inhibitors as anticancer agents. Drug Discov Today 2007; 12: 853-9.
15. Li Z, Tanaka H, Galiano F, Glass J. Anticancer activity of the iron facilitator LS081. J Exp Clin Cancer Res 2011; 30: 34.
16. Sasaki K, Ikuta K, Tanaka H et al. Improved quantification for non-transferrin-bound iron measurement using high performance liquid chromatography by reducing iron contamination. Mol Med Report 2011; 4: 913-8.
17. Gurusamy K. Trace element concentration in primary liver cancers-a systematic review. Biol Trace Elem Res 2007; 118: 191-206.
18. Hirota N, Williams GM. The sensitivity and heterogeneity of histochemical markers for altered foci involved in liver carcinogenesis. Am J Pathol 1979; 95: 317-28.
19. Hirota N, Williams GM. Ultrastructural abnormalities in carcinogen-induced hepatocellular altered foci identified by resistance to iron accumulation. Cancer Res 1982; 42: 2298-309.
20. Holmström P, Gåfvels M, Eriksson LC et al. Expression of iron regulatory genes in a rat model of hepatocellular carcinoma. Liver Int 2006; 26: 976-85.
21. Peyssonnaux C, Zinkernagel AS, Schuepbach RA et al. Regulation of iron homeostasis by the hypoxia-inducible transcription factors (HIFs). J Clin Invest 2007; 117: 1926-32.
22. Peyssonnaux C, Nizet V, Johnson RS. Role of the hypoxia inducible factors HIF in iron metabolism. Cell Cycle 2008; 7: 28-32.
23. Metzen E, Stiehl DP, Doege K et al. Regulation of the prolyl hydroxylase domain protein 2 (phd2/egln-1) gene: identification of a functional hypoxia-responsive element. Biochem J 2005; 387: 711-7.
24. Demidenko ZN, Blagosklonny MV. The purpose of the HIF-1/PHD feedback loop: to limit mTOR-induced HIF-1α. Cell Cycle 2011; 10: 1557-62.
25. Jokilehto T, Jaakkola PM. The role of HIF prolyl hydroxylases in tumour growth. J Cell Mol Med 2010; 14: 758-70.
26. Crichton RR, Wilmet S, Legssyer R, Ward RJ. Molecular and cellular mechanisms of iron homeostasis and toxicity in mammalian cells. J Inorg Biochem 2002; 91: 9-18.
27. Kohgo Y, Ikuta K, Ohtake T, Torimoto Y, Kato J. Body iron metabolism and pathophysiology of iron overload. Int J Hematol 2008; 88: 7-15.
28. Ponka P, Borová J, Neuwirt J, Fuchs O. Mobilization of iron from reticulocytes. Identification of pyridoxal isonicotinoyl hydrazone as a new iron chelating agent. FEBS Lett 1979; 97: 317-21.
29. Richardson DR, Tran EH, Ponka P. The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents. Blood 1995; 11: 4295-306.